GLPwatch
Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.
JAMA · 2023
Last updated 2026-07-12| Journal | JAMA, 2023 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.55 |
| NIH percentile | 32 |
| Molecules | retatrutide |
Full record and abstract on PubMed 37405802 ↗
Related research
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
- The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.